Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office 11 April 2023
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial 05 April 2023
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates 28 February 2023
